CLINICAL STUDY ON 6059-S

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement7; pp. 450 - 454
• Main Authors: HARADA, KEIICHI, HIGASHI, FUYUHIKO, FUJIMORI, IPPEI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 01.01.1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement7_450

6059-S, a new oxacephem antibiotic, was administered to 15 cases with urinary tract infection (11 cases of pyelonephritis) or respiratory tract infection (3 cases of acute pneumonia and one case of lung abscess). The daily dosages of 0.5 to 2.0 g were used in 11 cases of pyelonephritis in two divided doses by intramuscular or intravenous injection and 2.0 g used in 4 cases of respiratory tract infections in two divided doses by intravenous injection or intravenous drip infusion.Administration period was 5 to 15 days and total doses given were 3.5 to 30.0 g. Excellent or good clinical response was observed in 8 cases and overall clinical efficacy rate was 93.3% including 6 cases of fair response.As for bacteriological response in 13 strains of organisms isolated from 12 cases, the organisms from 8 cases (66.7%) were eradicated, but one case changed to other organism and 3 cases persisted. Regarding side effects, elevation of S-GOT and S-GPT were observed in one patient and decrease of WBC count in another one.However, they readily returned to normal values after discontinuance of the administration. No other side effects nor adverse reactions on clinical laboratory findings were observed. From these results, 6059-S is considered to be considerably useful injectable antibiotic as compared to existing other β-lactam antibiotics.